Acusensus (ASX: ACE) Surges 8% as WA Contract Doubles- But Can a $376M Pipeline Deliver Profits?

Ujjwal Maheshwari Ujjwal Maheshwari, February 11, 2026

Acusensus Surges as WA Contract Doubles

Acusensus (ASX: ACE) climbed 8 per cent on Tuesday, and what stood out was not just the contract itself but what it says about the company’s trajectory. By doubling its Western Australia enforcement fleet to twelve units and extending the partnership through October 2028, Acusensus added another A$13 million to a pipeline that has grown 84 per cent in twelve months to A$376 million. Government agencies across five Australian jurisdictions, New Zealand, and six US jurisdictions are now using the company’s AI platform to catch dangerous drivers. That kind of global traction from a small-cap is rare. But the stock still divides opinion because all this growth has not yet produced a profit, and understanding why is key to deciding whether ACE belongs in your portfolio.

What are the Best ASX Tech Stocks to invest in right now?

Check our buy/sell tips

Acusensus Builds a Global AI Road Safety Platform as Contracts Accelerate

The reason governments keep signing up is simple. Acusensus has built an AI-powered platform that detects multiple offences at once- mobile phone use, seatbelt violations, speeding, and unregistered vehicles, all from a single trailer. One piece of equipment replaces what used to require several, making it a cost-effective choice for road safety agencies.

Domestically, the company operates across five Australian jurisdictions. But the international expansion is where things get really interesting. In New Zealand, Acusensus won a nationwide speed camera contract worth up to NZ$92 million over five years. In the United States, its footprint grew from one jurisdiction to six in twelve months, headlined by a breakthrough AU$34 million Connecticut deal.

This momentum suggests the platform resonates strongly with government clients globally. Management has upgraded FY26 revenue guidance to A$83 million to A$87 million, roughly 40 to 46 per cent growth over last year. For a small cap, that acceleration is hard to find.

Revenue Is Surging, But Where Are the Profits?

Here is where the picture gets complicated. Despite growing revenue by 20 per cent in FY25, Acusensus posted a net loss of A$2.6 million, wider than the prior year’s A$1.5 million loss. What concerns us more is that adjusted EBITDA declined even as the top line grew, suggesting the company is spending heavily to win and deliver contracts before they become profitable.

To fund its global push, Acusensus raised A$30 million in December at A$1.50 per share, diluting shareholders by around 14 per cent. The Redflex patent settlement added another AU$16 million in costs. On the brighter side, operating cash flow jumped 131 per cent to A$8.3 million, and the company held A$21.5 million in cash at FY25, later bolstered by the A$30 million raise.

This is a business model that demands patience. Heavy upfront spending is the price of building a global contract base, and the payoff only arrives when operating leverage kicks in.

The Investor’s Takeaway

The bull case is straightforward: 40-plus per cent revenue growth, a A$376 million contracted pipeline, accelerating global expansion, and a unique AI platform with few direct competitors. At roughly A$300 million market capitalisation and A$1.85 per share, the stock trades at around 3.5 times upgraded FY26 revenue guidance, not unreasonable for this growth rate.

The bear case centres on profitability. Margins are not yet expanding despite strong revenue growth; the recent raise was dilutive, and government contracts can carry termination provisions. Investors should watch the New Zealand revenue ramp and the US pipeline closely for signs of margin improvement over the next one to two reporting periods.

In our view, the growth trajectory is compelling, and the pipeline provides genuine revenue visibility. For growth investors comfortable with near-term losses, the risk-reward looks attractive. Conservative investors may prefer to wait for evidence that revenue growth is finally reaching the bottom line.

Blog Categories

Get Our Top 5 ASX Stocks for FY26

Recent Posts

CSL (ASX:CSL) CEO Exit Shock, Then Results, What’s Real vs Noise

A Volatile Print, But Not a Broken Franchise Investors should brace for a bumpy ride with CSL right now. The…

CSL CEO Paul McKenzie has departed, now what for the fallen biotech giant?

In a bombshell 4pm announcement, investors learned that CSL CEO Paul McKenzie was departing the company effective that very afternoon…

Bitcoin Crashes 45% From Record Highs – Is It Time to Buy the Dip Through ASX Bitcoin ETFs?

Bitcoin has had a shocking few months. The world’s biggest cryptocurrency has lost nearly half its value since October 2025,…